BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. Clin Ther 2017;39:2158-68. [PMID: 29074312 DOI: 10.1016/j.clinthera.2017.09.013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. Oncologist 2019;24:e662-70. [PMID: 30651397 DOI: 10.1634/theoncologist.2018-0236] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Saavedra C, Barriuso J, McNamara MG, Valle JW, Lamarca A. Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes. Cancer Manag Res 2019;11:7537-56. [PMID: 31496810 DOI: 10.2147/CMAR.S181439] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 Ohlsson H, Wahlberg G, Malmström M, Gustafsson R, Sundlöv A, Nordenström E, Almquist M. Impact of Specific Bowel Symptoms on Quality of Life in Patients with Midgut Neuroendocrine Tumours. World J Surg 2021;45:2793-803. [PMID: 33969447 DOI: 10.1007/s00268-021-06146-9] [Reference Citation Analysis]
4 de Vries FE, Godthelp A, Spruit JR, Ruissen AM, Tesselaar MET, Boekhout AH. Coping with social consequences of disease-related symptoms in patients with a metastatic small intestinal neuroendocrine tumour: A qualitative study. J Neuroendocrinol 2021;33:e12956. [PMID: 33733525 DOI: 10.1111/jne.12956] [Reference Citation Analysis]
5 Simon TA, Khouri MS, Kou TD, Gomez-Caminero A. Realizing the Potential of the Patient Perspective. Patient Prefer Adherence 2020;14:2001-7. [PMID: 33132698 DOI: 10.2147/PPA.S257355] [Reference Citation Analysis]
6 Bader M. Inhibition of serotonin synthesis: A novel therapeutic paradigm. Pharmacol Ther 2020;205:107423. [PMID: 31629717 DOI: 10.1016/j.pharmthera.2019.107423] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
7 Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome. J Gastrointest Cancer 2021;52:212-21. [PMID: 32146619 DOI: 10.1007/s12029-020-00375-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Benson AB 3rd, Strosberg J, Joish VN, Dharba S, Sapre D, Lapuerta P. Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study. Pancreas 2020;49:408-12. [PMID: 32132510 DOI: 10.1097/MPA.0000000000001496] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics (Sao Paulo). 2018;73:e490s. [PMID: 30133565 DOI: 10.6061/clinics/2018/e490s] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
10 Hudgens S, Ramage J, Kulke M, Bergsland E, Anthony L, Caplin M, Öberg K, Pavel M, Gable J, Banks P, Yang QM, Lapuerta P. Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome. J Patient Rep Outcomes 2019;3:64. [PMID: 31655936 DOI: 10.1186/s41687-019-0153-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Ervin C, Joish VN, Evans E, Dibenedetti D, Reaney M, Preblick R, Castro R, Danne T, Buse JB, Lapuerta P. Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of Sotagliflozin. Clinical Therapeutics 2019;41:2219-2230.e6. [DOI: 10.1016/j.clinthera.2019.09.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Contesse MG, Valentine JE, Wall TE, Leffler MG. The Case for the Use of Patient and Caregiver Perception of Change Assessments in Rare Disease Clinical Trials: A Methodologic Overview. Adv Ther 2019;36:997-1010. [PMID: 30879250 DOI: 10.1007/s12325-019-00920-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
13 Dasari A, Joish VN, Perez-olle R, Dharba S, Balaji K, Halperin DM. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. Expert Review of Pharmacoeconomics & Outcomes Research 2020;20:507-11. [DOI: 10.1080/14737167.2019.1660646] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
14 Eads JR, Reidy-Lagunes D, Soares HP, Chan JA, Anthony LB, Halfdanarson TR, Naraev BG, Wolin EM, Halperin DM, Li D, Pommier RF, Zacks JS, Morse MA, Metz DC; from the Carcinoid Syndrome Control Collaborative. Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. Pancreas 2020;49:1123-30. [PMID: 32991344 DOI: 10.1097/MPA.0000000000001658] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Strosberg J, Joish VN, Giacalone S, Perez-Olle R, Fish-Steagall A, Kapoor K, Dharba S, Lapuerta P, Benson AB. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. Oncologist 2019;24:1446-52. [PMID: 31189618 DOI: 10.1634/theoncologist.2018-0921] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
16 Jin XF, Spampatti MP, Spitzweg C, Auernhammer CJ. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. Rev Endocr Metab Disord 2018;19:145-58. [PMID: 29464446 DOI: 10.1007/s11154-018-9443-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
17 Pan IW, Halperin DM, Kim B, Yao JC, Shih YT. A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. Pharmacoeconomics 2021. [PMID: 34378163 DOI: 10.1007/s40273-021-01071-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, Ramage J, Pavel M, Hörsch D, Kulke MH. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. Clin Ther 2018;40:2006-2020.e2. [PMID: 30477789 DOI: 10.1016/j.clinthera.2018.10.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
19 Anthony LB, O'Dorisio TM. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist 2021;26:e1171-8. [PMID: 34097784 DOI: 10.1002/onco.13847] [Reference Citation Analysis]
20 Fust K, Maschio M, Kohli M, Singh S, Pritchard DM, Marteau F, Myrenfors P, Feuilly M. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome. PharmacoEconomics 2020;38:607-18. [DOI: 10.1007/s40273-020-00896-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World J Gastroenterol 2019; 25(47): 6857-6865 [PMID: 31885426 DOI: 10.3748/wjg.v25.i47.6857] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Hallet J, Davis LE, Mahar AL, Isenberg-grzeda E, Bubis LD, Myrehaug S, Zhao H, Beyfuss K, Moody L, Law CHL, Coburn NG. Symptom Burden at the End of Life for Neuroendocrine Tumors: An Analysis of 2579 Prospectively Collected Patient-Reported Outcomes. Ann Surg Oncol 2019;26:2711-21. [DOI: 10.1245/s10434-019-07441-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
23 Lyseng-Williamson KA. Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea. Drugs. 2018;78:941-950. [PMID: 29931594 DOI: 10.1007/s40265-018-0935-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]